Cited by 2,096Erythropoietin and Anemia TreatmentDialysis and Renal Disease ManagementChronic Kidney Disease and Diabetes

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease

Open access

Pfeffer, Marc A., Burdmann, Emmanuel A., Chen, Chao-Yin, Cooper, Mark E., de Zeeuw, Dick, Eckardt, Kai-Uwe, Feyzi, Jan M., Ivanovich, Peter, Kewalramani, Reshma, Levey, Andrew S., Lewis, Eldrin F., McGill, Janet B., McMurray, John J.V., Parfrey, Patrick, Parving, Hans-Henrik, Remuzzi, Giuseppe, Singh, Ajay K., Solomon, Scott D., Toto, Robert·2009·New England Journal of Medicine

DOI 10.1056/nejmoa0907845

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Anemia is associated with an increased risk of cardiovascular and renal events among patients with type 2 diabetes and chronic kidney disease. Although darbepoetin alfa can effectively increase hemoglobin levels, its effect on clinical outcomes in these patients has not been adequately tested. METHODS: In this study involving 4038 patients with diabetes, chronic kidney disease, and anemia, we randomly assigned 2012 patients to darbepoetin alfa to achieve a hemoglobin level of approximately 13 g per deciliter and 2026 patients to placebo, with rescue darbepoetin alfa when the hemoglobin level was less than 9.0 g per deciliter. The primary end points were the composite outcomes of death or a cardiovascular event (nonfatal myocardial infarction, congestive heart failure, stroke, or hospitalization for myocardial ischemia) and of death or end-stage renal disease. RESULTS: Death or a cardiovascular event occurred in 632 patients assigned to darbepoetin alfa and 602 patients assigned to placebo (hazard ratio for darbepoetin alfa vs. placebo, 1.05; 95% confidence interval [CI], 0.94 to 1.17; P=0.41). Death or end-stage renal disease occurred in 652 patients assigned to darbepoetin alfa and 618 patients assigned to placebo (hazard ratio, 1.06; 95% CI, 0.95 to 1.19; P=0.29). Fatal or nonfatal stroke occurred in 101 patients assigned to darbepoetin alfa and 53 patients assigned to placebo (hazard ratio, 1.92; 95% CI, 1.38 to 2.68; P<0.001). Red-cell transfusions were administered to 297 patients assigned to darbepoetin alfa and 496 patients assigned to placebo (P<0.001). There was only a modest improvement in patient-reported fatigue in the darbepoetin alfa group as compared with the placebo group. CONCLUSIONS: The use of darbepoetin alfa in patients with diabetes, chronic kidney disease, and moderate anemia who were not undergoing dialysis did not reduce the risk of either of the two primary composite outcomes (either death or a cardiovascular event or death or a renal event) and was associated with an increased risk of stroke. For many persons involved in clinical decision making, this risk will outweigh the potential benefits. (ClinicalTrials.gov number, NCT00093015.)

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa0907845

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citation
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Self-citation
Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial
Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Self-citation
Correction of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762
Self-citation
Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
Drüeke, T. B., Locatelli, F., Clyne, N., Eckardt, K., Macdougall, I. C., Tsakiris, D., Burger, H.-U., & Scherhag, A. W. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062276 · Cited by 2,094
Self-citation
Recombinant Human Erythropoietin in Anemic Patients with End-Stage Renal Disease: Results of a Phase III Multicenter Clinical Trial
Eschbach, J. W., Abdulhadi, M. H., Browne, J. K., Delano, B. G., Downing, M. R., Egrie, J. C., Evans, R. W., Friedman, E. A., Graber, S. E., Haley, N. R., et al. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-12-992 · Cited by 795
Effects of Different Blood Pressure–Lowering Regimens on Major Cardiovascular Events in Individuals With and Without Diabetes Mellitus
Blood Pressure Lowering Treatment Trialists’ Collaboration (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.12.1410 · Cited by 789
Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study
Booth, G. L., Kapral, M. K., Fung, K., & Tu, J. V. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68967-8 · Cited by 782

Flagged first, then by citations

Show all 32 references

Research works printed but not linked: 2

Pfeffer MA, 2005, Rev Cardiovasc Med, 3, S35
Strippoli GF, 2006, Cochrane Database Syst Rev, 4, CD003967

Sorted by citations

Items 101–200 of 1,000

Erythropoietin Contrastingly Affects Bacterial Infection and Experimental Colitis by Inhibiting Nuclear Factor-κB-Inducible Immune Pathways
Nairz, M., Schroll, A., Moschen, A. R., Sonnweber, T., Theurl, M., Theurl, I., Taub, N., Jamnig, C., Neurauter, D., Huber, L. A., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.01.002 · Cited by 194
Cardiorenal Syndrome
Kumar, U., Wettersten, N. W., & Garimella, P. S. (2019) · Cardiology Clinics · doi:10.1016/j.ccl.2019.04.001 · Cited by 193
Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study
Fishbane, S. N., El-Shahawy, M. A., Pecoits‐Filho, R., Van, B. P., Houser, M. T., Frison, L., Little, D. J., Guzman, N. J., & Pérgola, P. E. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020081150 · Cited by 193
Diets and enteral supplements for improving outcomes in chronic kidney disease
Kalantar‐Zadeh, K., Cano, N., Budde, K., Chazot, C., Kovesdy, C. P., MAK, R. H. K., Mehrotra, R., Raj, D. S., Sehgal, A. R., Stenvinkel, P., et al. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.60 · Cited by 195
Cancer- and Chemotherapy-Induced Anemia
_, _. (2008) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2008.0042 · Cited by 192
Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience
Sanghani, N. S., & Haase, V. H. (2019) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.04.004 · Cited by 188
Fatigue in CKD
Gregg, L. P., Bossola, M., Ostrosky-Frid, M., & Hedayati, S. S. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.19891220 · Cited by 187
Vascular Incompetence in Dialysis Patients—Protein‐Bound Uremic Toxins and Endothelial Dysfunction
Jourde‐Chiche, N., Dou, L., Cérini, C., Dignat‐George, F., & Brunet, P. (2011) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2011.00925.x · Cited by 193
Hemodialysis‐induced cardiovascular disease
Ahmadmehrabi, S., & Tang, W. H. W. (2018) · Seminars in Dialysis · doi:10.1111/sdi.12694 · Cited by 191
The Influence of Inflammation on Anemia in CKD Patients
Gluba-Brzózka, A., Franczyk, B., Olszewski, R., & Rysz, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030725 · Cited by 192
Poststroke Fatigue: Emerging Evidence and Approaches to Management: A Scientific Statement for Healthcare Professionals From the American Heart Association
Hinkle, J. L., Becker, K. J., Kim, J. S., Choi‐Kwon, S., Saban, K. L., McNair, N. D., & Mead, G. E. (2017) · Stroke · doi:10.1161/str.0000000000000132 · Cited by 189
Critical and Honest Conversations
Williams, A. W., Dwyer, A. C., Eddy, A. A., Fink, J. C., Jaber, B. L., Linas, S. L., Michael, B., O’Hare, A. M., Schaefer, H. M., Shaffer, R. N., et al. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04970512 · Cited by 184
Sodium–glucose cotransporter 2 inhibition suppresses HIF-1α-mediated metabolic switch from lipid oxidation to glycolysis in kidney tubule cells of diabetic mice
Cai, T., Ke, Q., Fang, Y., Wen, P., Chen, H., Yuan, Q., Luo, J., Zhang, Y., Sun, Q., Lv, Y., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2544-7 · Cited by 185
Kidney and heart failure outcomes associated with SGLT2 inhibitor use
der Beek, A. B. V. D. A., de Boer, R. A., & Heerspink, H. J. L. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00535-6 · Cited by 186
Targeting the hepcidin–ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation
Sun, C. C., Vaja, V., Babitt, J. L., & Lin, H. Y.-F. (2011) · American Journal of Hematology · doi:10.1002/ajh.23110 · Cited by 185
The role of iron repletion in adult iron deficiency anemia and other diseases
Elstrott, B. K., Khan, L., Olson, S. R., Raghunathan, V. M., DeLoughery, T. G., & Shatzel, J. J. (2019) · European Journal Of Haematology · doi:10.1111/ejh.13345 · Cited by 182
Treatment of chronic kidney disease
Turner, J. M., Bauer, C. A., Abramowitz, M. K., Melamed, M. L., & Hostetter, T. H. (2011) · Kidney International · doi:10.1038/ki.2011.380 · Cited by 187
The glycocalyx—linking albuminuria with renal and cardiovascular disease
Rabelink, T. J., & de Zeeuw, D. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.162 · Cited by 180
Does AKI Truly Lead to CKD?
Rifkin, D. E., Coca, S. G., & Kalantar‐Zadeh, K. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011121185 · Cited by 171
Anemia in cancer
Dicato, M. A., Plawny, L., & Diederich, M. F. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq284 · Cited by 171
Molecular Dysfunction and Phenotypic Derangement in Diabetic Cardiomyopathy
Evangelista, I., Nuti, R., Picchioni, T., Dotta, F., & Palazzuoli, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133264 · Cited by 172
Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial
Pisani, A., Riccio, E., Sabbatini, M., Andreucci, M., Rio, A. D., & Visciano, B. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu357 · Cited by 164
Stage IV Chronic Kidney Disease
Abboud, H. E., & Henrich, W. L. (2010) · New England Journal of Medicine · doi:10.1056/nejmcp0906797 · Cited by 170
Results of a reevaluation of cardiovascular outcomes in the RECORD trial
Mahaffey, K. W., Hafley, G. E., Dickerson, S., Burns, S., Tourt-Uhlig, S., White, J. A., Newby, L. K., Michel Komajda, N., McMurray, J. J. V., Bigelow, R., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.05.004 · Cited by 165
Self-citation
HIF‐prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism
Haase, V. H. (2017) · Hemodialysis International · doi:10.1111/hdi.12567 · Cited by 164
Heart Failure in Patients with Chronic Kidney Disease: A Systematic Integrative Review
Segall, L., Nistor, I., & Covic, A. C. (2014) · BioMed Research International · doi:10.1155/2014/937398 · Cited by 164
Vascular Risk Factors and Cognitive Impairment in Chronic Kidney Disease
Tamura, M. K., Xie, D., Yaffe, K. S., Cohen, D. L., Teal, V. L., Kasner, S. E., Messe, S. R., Sehgal, A. R., Kusek, J. W., DeSalvo, K. B., et al. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02660310 · Cited by 162
Chronic Kidney Disease and Cerebrovascular Disease
Kelly, D., Ademi, Z., Doehner, W., Lip, G. Y. H., Mark, P. B., Toyoda, Ḱ., Wong, C. X. J., Sarnak, M. J., Cheung, M., Herzog, C. A., et al. (2021) · Stroke · doi:10.1161/strokeaha.120.029680 · Cited by 167
Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES)
Barratt, J., Andrić, B., Tataradze, A., Schömig, M., Reusch, M., Valluri, U., & Mariat, C. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab191 · Cited by 157
Post-acute delivery of erythropoietin induces stroke recovery by promoting perilesional tissue remodelling and contralesional pyramidal tract plasticity
Reitmeir, R., Kilic, E., Kilic, Ü., Bacigaluppi, M., ElAli, A., Salani, G., Pluchino, S., Gassmann, M., & Hermann, D. M. (2011) · Brain · doi:10.1093/brain/awq344 · Cited by 156
Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Ku, E., Vecchio, L. D., Eckardt, K., Haase, V. H., Johansen, K. L., Nangaku, M., Tangri, N., Waikar, S. S., Więcek, A., Cheung, M., et al. (2023) · Kidney International · doi:10.1016/j.kint.2023.05.009 · Cited by 162
Self-citation
Intravenous Ferric Carboxymaltose in Iron-Deficient Chronic Heart Failure Patients with and Without Anaemia: a Subanalysis of the FAIR-HF Trial
Filippatos, G. S., Farmakis, D. T., Colet, J. C., Dickstein, K., Lüscher, T. F., Willenheimer, R. B., Parissis, J., Gaudesius, G., Mori, C., Rothe, B. V. E., et al. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft099 · Cited by 158
Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study
Fishbane, S., Pollock, C. A., El-Shahawy, M., Escudero, E. T., Rastogi, A., Van, B. P., Frison, L., Houser, M., Pola, M., Little, D. J., et al. (2022) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020111638 · Cited by 161
Infection Risk with Bolus versus Maintenance Iron Supplementation in Hemodialysis Patients
Brookhart, M. A., Freburger, J. K., Ellis, A. R., Wang, L. H.-C., Winkelmayer, W. C., & Kshirsagar, A. V. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012121164 · Cited by 153
A 12-Week, Double-Blind, Placebo-Controlled Trial of Ferric Citrate for the Treatment of Iron Deficiency Anemia and Reduction of Serum Phosphate in Patients With CKD Stages 3-5
Block, G. A., Fishbane, S. N., Rodríguez, M., Smits, G., Shemesh, S., Pérgola, P. E., Wolf, M. S., & Chertow, G. M. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.10.014 · Cited by 154
Nitric oxide signaling in hypoxia
Ho, J. J. D., Man, H. S. J., & Marsden, P. A. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0880-5 · Cited by 155
Dialysis Fistula or Graft
Allon, M., & Lok, C. E. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06050710 · Cited by 151
Erythropoietin as neuroprotective and neuroregenerative treatment strategy: Comprehensive overview of 12 years of preclinical and clinical research
Sargin, D., Friedrichs, H., El-Kordi, A., & Ehrenreich, H. (2010) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2010.10.005 · Cited by 150
Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease
Sugahara, M., Tanaka, T., & Nangaku, M. (2017) · Kidney International · doi:10.1016/j.kint.2017.02.035 · Cited by 151
Cerebro-renal interactions: Impact of uremic toxins on cognitive function
Watanabe, K., Watanabe, T., & Nakayama, M. (2014) · NeuroToxicology · doi:10.1016/j.neuro.2014.06.014 · Cited by 145
Poststroke Fatigue: An Emerging, Critical Issue in Stroke Medicine
Choi‐Kwon, S., & Kim, J. S. (2011) · International Journal of Stroke · doi:10.1111/j.1747-4949.2011.00624.x · Cited by 144
Diagnosis and management of anaemia of chronic disease: current status
Cullis, J. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08741.x · Cited by 144
Cardiorenal syndrome—current understanding and future perspectives
Braam, B. G., Joles, J. A., Danishwar, A. H., & Gaillard, S. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.250 · Cited by 145
A single dose of erythropoietin in ST-elevation myocardial infarction
Voors, A. A., Belonje, A. M. S., Zijlstra, F., Hillege, H. L., Anker, S. D., Slart, R. H. J. A., Tio, R. A., Hof, A. W. J. V. ’., Jukema, J. W., Peels, H. O., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq304 · Cited by 144
Chapter 3: Management of progression and complications of CKD
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.66 · Cited by 144
Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp(R) Therapy (TREAT) Study
Locatelli, F., Aljama, P., Canaud, B., Covic, A. C., de Francisco, A., Macdougall, I. C., Więcek, A., Vanholder, R., & On behalf of the Anaemia Working Group of European Renal Best Practice (ERBP) (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq336 · Cited by 142
Anaemia management and mortality risk in chronic kidney disease
Hörl, W. H. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.21 · Cited by 143
An international observational study suggests that artificial intelligence for clinical decision support optimizes anemia management in hemodialysis patients
Barbieri, C., Molina, M., Ponce, P., Tothová, M., Cattinelli, I., Titapiccolo, J. I., Mari, F., Amato, C., Leipold, F., Wehmeyer, W., et al. (2016) · Kidney International · doi:10.1016/j.kint.2016.03.036 · Cited by 141
Current misconceptions in diagnosis and management of iron deficiency.
Múñoz, M., Gómez‐Ramírez, S., Besser, M. W., Pavı́a, J., Gomollón, F., Liumbruno, G. M., Bhandari, S., Cladellas, M., Shander, A., & Auerbach, M. (2017) · PubMed Central · doi:10.2450/2017.0113-17 · Cited by 149
Perioperative Anemia: Prevention, Diagnosis, and Management Throughout the Spectrum of Perioperative Care
Warner, M. A., Shore-Lesserson, L. J., Shander, A., Patel, S. Y., Perelman, S. I., & Guinn, N. R. (2020) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000004727 · Cited by 144
The Effect of Iron and Erythropoietin Treatment on the A1C of Patients With Diabetes and Chronic Kidney Disease
Ng, J. M., Cooke, M., Bhandari, S., Atkin, S. L., & Kilpatrick, E. S. (2010) · Diabetes Care · doi:10.2337/dc10-0917 · Cited by 143
Anemia and iron deficiency among chronic kidney disease Stages 3–5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated
Wong, M. M. Y., Tu, C., Li, Y., Perlman, R. L., Pecoits-Filho, R., Lopes, A. A., Narita, I., Reichel, H., Port, F. K., Sukul, N., et al. (2020) · Clinical Kidney Journal · doi:10.1093/ckj/sfz091 · Cited by 140
Association Between Cardiac Biomarkers and the Development of ESRD in Patients With Type 2 Diabetes Mellitus, Anemia, and CKD
Desai, A. S., Toto, R. D., Jarolı́m, P., Uno, H., Eckardt, K., Kewalramani, R., Levey, A. S., Lewis, E. F., McMurray, J. J. V., Parving, H., et al. (2011) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.05.020 · Cited by 141
Self-citation
Iron supplementation to treat anemia in patients with chronic kidney disease
Besarab, A., & Coyne, D. W. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.139 · Cited by 142
Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis
Palmer, S. C., Saglimbene, V. M., Mavridis, D., Salanti, G., Craig, J. C., Tonelli, M. A., Wiebe, N., & Strippoli, G. F. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010590.pub2 · Cited by 144
High sensitivity cardiac troponin assays in the clinical laboratories
Jarolı́m, P. (2014) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2014-0565 · Cited by 138
Blood Transfusions in Organ Transplant Patients: Mechanisms of Sensitization and Implications for Prevention
Scornik, J. C., & Meier‐Kriesche, H. (2011) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03705.x · Cited by 137
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial
Oshima, M., Neuen, B. L., Jardine, M. J., Bakris, G., Edwards, R., Levin, A., Mahaffey, K. W., Neal, B., Pollock, C., Rosenthal, N., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30300-4 · Cited by 135
Anemia in chronic kidney disease
Atkinson, M. A., & Warady, B. A. (2017) · Pediatric Nephrology · doi:10.1007/s00467-017-3663-y · Cited by 135
The roles of HIF-1α signaling in cardiovascular diseases
Sato, T., & Takeda, N. (2022) · Journal of Cardiology · doi:10.1016/j.jjcc.2022.09.002 · Cited by 135
Correction of Postkidney Transplant Anemia Reduces Progression of Allograft Nephropathy
Choukroun, G. J., Kamar, N., Dussol, B., Étienne, I., Cassuto, É., Toupance, O., Glowacki, F., Moulin, B., Lebranchu, Y., Touchard, G., et al. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011060546 · Cited by 132
Cardiovascular Toxicity of Epoetin-Alfa in Patients with Chronic Kidney Disease
McCullough, P. A., Barnhart, H. X., Inrig, J. K., Reddan, D. N., Sapp, S. K., Patel, U. D., Singh, A. K., Szczech, L. A. M., & Califf, R. M. (2013) · American Journal of Nephrology · doi:10.1159/000351175 · Cited by 131
Self-citation
Erythropoietin Action in Stress Response, Tissue Maintenance and Metabolism
Zhang, Y., Wang, L., Dey, S., Alnaeeli, M., Suresh, S., Rogers, H. M., Teng, R., & Noguchi, C. T. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150610296 · Cited by 132
Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease
Martin, E. R., Smith, M. T., Maroni, B. J., Zuraw, Q., & deGoma, E. M. (2017) · American Journal of Nephrology · doi:10.1159/000464476 · Cited by 129
Differentiating Factors Between Erythropoiesis-Stimulating Agents: An Update to Selection for Anaemia of Chronic Kidney Disease
Hörl, W. H. (2013) · Drugs · doi:10.1007/s40265-012-0002-2 · Cited by 128
Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS)
Shutov, E. V., Sułowicz, W., Esposito, C., Tataradze, A., Andrić, B., Reusch, M., Valluri, U., & Dimkovic, N. B. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab057 · Cited by 126
Anemia of Chronic Disease
Gangat, N., & Wolanskyj, A. P. (2013) · Seminars in Hematology · doi:10.1053/j.seminhematol.2013.06.006 · Cited by 127
Hemorheology and Microvascular Disorders
Cho, Y. I., & Cho, D. J. (2011) · Korean Circulation Journal · doi:10.4070/kcj.2011.41.6.287 · Cited by 130
Medication Safety Principles and Practice in CKD
Whittaker, C. F., Miklich, M. A., Patel, R. S., & Fink, J. C. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00580118 · Cited by 129
The Impact of CKD Anaemia on Patients: Incidence, Risk Factors, and Clinical Outcomes—A Systematic Literature Review
Palaka, E., Grandy, S., van Haalen, H., McEwan, P. C., & Darlington, O. T. (2020) · International Journal of Nephrology · doi:10.1155/2020/7692376 · Cited by 125
Chronic kidney disease and heart failure—Bidirectional close link and common therapeutic goal
Shiba, N., & Shimokawa, H. (2010) · Journal of Cardiology · doi:10.1016/j.jjcc.2010.09.004 · Cited by 125
Comparative Mortality Risk of Anemia Management Practices in Incident Hemodialysis Patients
Brookhart, M. A. (2010) · JAMA · doi:10.1001/jama.2010.206 · Cited by 124
Perioperative Management of Patients With End-Stage Renal Disease
Kanda, H., Hirasaki, Y., Iida, T., Kanao-Kanda, M., Toyama, Y., Chiba, T., & Kunisawa, T. (2017) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2017.04.019 · Cited by 126
Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia
Akizawa, T., Nangaku, M., Yonekawa, T., Okuda, N., Kawamatsu, S., Onoue, T., Endo, Y., Hara, K., & Cobitz, A. R. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.16011219 · Cited by 123
Erythropoietin regulation of red blood cell production: from bench to bedside and back
Bhoopalan, S. V., Huang, L. J.-S., & Weiss, M. J. (2020) · F1000Research · doi:10.12688/f1000research.26648.1 · Cited by 132
Patient Perspectives on the Meaning and Impact of Fatigue in Hemodialysis: A Systematic Review and Thematic Analysis of Qualitative Studies
Jacobson, J., Ju, A., Baumgart, A., Unruh, M. L., O'Donoghue, D. J., Obrador, G. T., Craig, J. C., Dapueto, J. J., Dew, M. A., Germain, M. J., et al. (2019) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.01.034 · Cited by 126
Chronic kidney disease
Herrington, W. G., Judge, P. K., Grams, M. E., & Wanner, C. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01942-7 · Cited by 124
Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency Anemia
Fishbane, S. N., Block, G. A., Loram, L. C., Neylan, J. F., Pérgola, P. E., Uhlig, K., & Chertow, G. M. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016101053 · Cited by 120
Roxadustat for CKD-related Anemia in Non-dialysis Patients
Coyne, D. W., Roger, S. D., Shin, S. K., Kim, S. G., Cadena, A., Moustafa, M. A., Chan, T. M., Besarab, A., Chou, W., Bradley, C., et al. (2020) · Kidney International Reports · doi:10.1016/j.ekir.2020.11.034 · Cited by 126
Retracted
Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease
Charytan, D. M., Solomon, S. D., Ivanovich, P. T., Remuzzi, G., Cooper, M. E., McGill, J. B., Parving, H., Parfrey, P. S., Singh, A. K., Burdmann, E. A., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13642 · Cited by 119
Self-citation
Impact of chronic kidney disease and anemia on health-related quality of life and work productivity: analysis of multinational real-world data
van Haalen, H., Jackson, J., Spinowitz, B., Milligan, G., & Moon, R. (2020) · BMC Nephrology · doi:10.1186/s12882-020-01746-4 · Cited by 119
Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction
Pandey, A. K., Bhatt, D. L., Pandey, A. K., Marx, N., Cosentino, F., Pandey, A., & Verma, S. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad389 · Cited by 125
Peginesatide for Anemia in Patients with Chronic Kidney Disease Not Receiving Dialysis
Macdougall, I. C., Provenzano, R., Sharma, A. K., Spinowitz, B., Schmidt, R. J., Pérgola, P. E., Zabaneh, R. I., Tong-Starksen, S., Mayo, M. R., Tang, H., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1203166 · Cited by 116
Cardiovascular co-morbidity in chronic kidney disease: Current knowledge and future research needs
Alani, H. (2014) · World Journal of Nephrology · doi:10.5527/wjn.v3.i4.156 · Cited by 119
A single dose of erythropoietin reduces perioperative transfusions in cardiac surgery: results of a prospective single‐blind randomized controlled trial
Weltert, L. P., Rondinelli, B., Bello, R. A., Falco, M., Bellisario, A., Maselli, D., Turani, F., Paulis, R. D., & Pierelli, L. (2015) · Transfusion · doi:10.1111/trf.13027 · Cited by 116
Types of Erythropoietin-Stimulating Agents and Mortality among Patients Undergoing Hemodialysis
Sakaguchi, Y., Hamano, T., Wada, A., & Masakane, I. (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018101007 · Cited by 116
Role of B‐Type Natriuretic Peptide and N‐Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus
Wolsk, E., Claggett, B. L., Pfeffer, M. A., Díaz, R., Dickstein, K., Gerstein, H. C., Lawson, F. C., Lewis, E. F., Maggioni, A. P., McMurray, J. J. V., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004743 · Cited by 114
Self-citation
Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES)
Csiky, B. S., Schömig, M., Esposito, C., Barratt, J., Reusch, M., Valluri, U., & Sułowicz, W. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01904-6 · Cited by 116
Protective Role of Histidine Supplementation Against Oxidative Stress Damage in the Management of Anemia of Chronic Kidney Disease
Vera‐Aviles, M., Vantana, E., Kardinasari, E., Koh, N. L., & Latunde-Dada, G. O. (2018) · Pharmaceuticals · doi:10.3390/ph11040111 · Cited by 115
New Treatment Approaches for the Anemia of CKD
Bonomini, M., Vecchio, L. D., Sirolli, V., & Locatelli, F. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.06.030 · Cited by 115
Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis
Meadowcroft, A. M., Čižman, B., Holdstock, L., Biswas, N., Johnson, B. M., Jones, D., Nossuli, A. K. K., Lepore, J. J., Aarup, M., & Cobitz, A. R. (2018) · Clinical Kidney Journal · doi:10.1093/ckj/sfy014 · Cited by 111
Multiple‐dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA‐IgG1), a novel erythropoietic agent, in healthy postmenopausal women
Sherman, M. L., Borgstein, N. G., Mook, L., Wilson, D. M., Yang, Y., Chen, N., Kumar, R., Kim, K., & Laadem, A. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.160 · Cited by 111
Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients
Cody, J. D., Daly, C. D., Campbell, M., Khan, I. H., Rabindranath, K. S., Vale, L. D., Wallace, S. A., MacLeod, A. M., Grant, A., Pennington, S., et al. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003266.pub2 · Cited by 111
Effect of ultrapure dialysate on markers of inflammation, oxidative stress, nutrition and anemia parameters: a meta-analysis
Susantitaphong, P., Riella, C. V., & Jaber, B. L. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs514 · Cited by 110
Role of Deranged Energy Deprivation Signaling in the Pathogenesis of Cardiac and Renal Disease in States of Perceived Nutrient Overabundance
Packer, M. (2020) · Circulation · doi:10.1161/circulationaha.119.045561 · Cited by 113
Peginesatide in Patients with Anemia Undergoing Hemodialysis
Fishbane, S. N., Schiller, B. M., Locatelli, F., Covic, A. C., Provenzano, R., Więcek, A., Levin, N. W., Kaplan, M., Macdougall, I. C., Francisco, C. A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1203165 · Cited by 111
Risk Factors for Heart Failure in Patients With Chronic Kidney Disease: The CRIC (Chronic Renal Insufficiency Cohort) Study
He, J., Shlipak, M. G., Anderson, A., Roy, J. A., Feldman, H. I., Kallem, R. R., Kanthety, R., Kusek, J. W., OJO, A. O., Rahman, M., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005336 · Cited by 109
Effects of Molidustat in the Treatment of Anemia in CKD
Macdougall, I. C., Akizawa, T., Berns, J. S., Bernhardt, T., & Krueger, T. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02510218 · Cited by 107
Diabetes and Metabolism
Kowaltowski, A. J., & Abdulkader, F. (2020) · Springer eBooks · doi:10.1007/978-3-030-50968-2_9 · Cited by 106
Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects
Akizawa, T., Tsubakihara, Y., Nangaku, M., Endo, Y., Nakajima, H., Kohno, T., Imai, Y., Kawase, N., Hara, K., Lepore, J. J., et al. (2016) · American Journal of Nephrology · doi:10.1159/000454818 · Cited by 105

Authors: Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., Lewis, E. F., McGill, J. B., McMurray, J. J. V., Parfrey, P., Parving, H.-H., Remuzzi, G., Singh, A. K., Solomon, S. D., & Toto, R.
Affiliations: Brigham and Women's Hospital (US)
Hospital de Base (BR)
Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
University of Wisconsin–Madison (US)
Northwestern University (US)
Tufts University (US)
Harvard University (US)
Washington University in St. Louis (US)
University of Glasgow (GB)
University of Copenhagen (DK)
The University of Texas Southwestern Medical Center (US)
ORCID: Pfeffer, Marc A.
Burdmann, Emmanuel A.
Cooper, Mark E.
Eckardt, Kai-Uwe
Levey, Andrew S.
Lewis, Eldrin F.
McGill, Janet B.
McMurray, John J.V.
Remuzzi, Giuseppe
Singh, Ajay K.
Solomon, Scott D.
Toto, Robert
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2009-11-19
Volume: 361
Issue: 21
Pages: 2019-2032
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa0907845
OpenAlex: W1998943227
Cited by: 2,096
References: 32
Citations by year: 2026: 62 · 2025: 66 · 2024: 65 · 2023: 94 · 2022: 92 · 2021: 128 · 2020: 121 · 2019: 111 · 2018: 90 · 2017: 108 · 2016: 125 · 2015: 122 · 2014: 163 · 2013: 174 · 2012: 175
FWCI: 125.33
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
Funders: Robert Wood Johnson Foundation
Amgen
Bristol-Myers Squibb
Pfizer
AstraZeneca
GlaxoSmithKline
Sanofi
Biogen
Louisiana Board of Regents
Boston Scientific Corporation
McGill University
Celladon Corporation
Covis Pharma
Cytokinetics
Servier
Genentech
Daiichi Sankyo Europe
Topics: Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords: darbepoetin alfa, type 2 diabetes, chronic kidney disease, anemia, erythropoiesis-stimulating agents, cardiovascular events, end-stage renal disease, stroke, red blood cell transfusion, fatigue, hemoglobin target, cardiovascular risk reduction, non-dialysis patients
MeSH terms: Darbepoetin alfa, Aged, Anemia, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Erythropoietin, Female, Hematinics, Hemoglobins, Humans, Kidney Failure, Chronic, Male, Middle Aged, Neoplasms, Stroke, Renal Insufficiency, Chronic, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks